Copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2000
In their article in the November 1998 issue of the ARCHIVES, Rice and Ebers1 raised concerns about the best method for defining disease progression for patients with relapsing-remitting multiple sclerosis (MS) in clinical trials, and they cast doubt on the significance of disability progression as defined in the pivotal interferon beta-1a (IFN-β-1a) (Avonex; Biogen Inc, Cambridge, Mass) trial.2 I would like to comment, in part because I was quoted out of context in the article.
Rudick RA. How Does One Define Progression of Disease in Patients With Relapsing-Remitting Multiple Sclerosis?. Arch Neurol. 2000;57(3):425-426. doi: